Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07678970 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 10 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07718165 | A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration | recruiting | Phase 1 | 247 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03313778 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors(KEYNOTE-603) | active not recruiting | Phase 1 | 161 | ModernaTX, Inc.INDUSTRY | 4 | Sep 3, 2026 | clinicaltrials |
| NCT05518045 | A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 392 | LaNova Medicines LimitedINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07358260 | B7-H3.CD28Z.CART in Solid Tumors | recruiting | Phase 1 | 40 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07545265 | SKB565 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03440450 | A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer | active not recruiting | Phase 1 | 90 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04047251 | A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma | active not recruiting | Phase 1 | 96 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | recruiting | Phase 1 | 400 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06049212 | Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)(TroFuse-008) | active not recruiting | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06251310 | SW-682 in Advanced Solid Tumors | recruiting | Phase 1 | 186 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06507306 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | active not recruiting | Phase 1 | 92 | Kumquat Biosciences Inc.INDUSTRY | 4 | Sep 2, 2026 | clinicaltrials |
| NCT06795412 | Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 220 | Pyxis Oncology, IncINDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT06809530 | Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | active not recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07182591 | A Study of DS5361b in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 192 | Daiichi SankyoINDUSTRY | 2 | Sep 2, 2026 | clinicaltrials |
| NCT05327946 | A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated | active not recruiting | Phase 1 | 42 | Boehringer IngelheimINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT05958121 | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Immatics Biotechnologies GmbHINDUSTRY | 2 | Sep 1, 2026 | clinicaltrials |
| NCT06305247 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 36 | IpsenINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT06576037 | Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | recruiting | Phase 1 | 128 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06730750 | A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 360 | Bristol-Myers SquibbINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT06833008 | A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 85 | IpsenINDUSTRY | 4 | Sep 1, 2026 | clinicaltrials |
| NCT06983743 | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors(AURORAS-1) | recruiting | Phase 1 | 600 | Erasca, Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07161414 | A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy(ARTEMIDE-subQ) | recruiting | Phase 1 | 40 | AstraZenecaINDUSTRY | 4 | Sep 1, 2026 | clinicaltrials |
| NCT07213817 | A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours | recruiting | Phase 1 / Phase 2 | 114 | IpsenINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07700160 | First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | VelaVigo Bio IncINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT07797426 | A Study of RT023 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 318 | Shanghai Ruotuo Biosciences Co., Ltd.INDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT07797907 | This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer. | not yet recruiting | Phase 1 | 110 | Biolojic Design Ltd.INDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT04751786 | Dose Escalation Study of Immunomodulatory Nanoparticles(PRECIOUS-01) | active not recruiting | Phase 1 | 15 | Radboud University Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05536141 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors(ARC-20) | recruiting | Phase 1 | 362 | Arcus Biosciences, Inc.INDUSTRY | 4 | Aug 31, 2026 | clinicaltrials |
| NCT06193902 | LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.(AERIAL) | recruiting | Phase 1 / Phase 2 | 17 | Leucid BioINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07793825 | A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 90 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02142803 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | active not recruiting | Phase 1 | 498 | Genentech, Inc.INDUSTRY | 17 | Aug 28, 2026 | clinicaltrials |
| NCT06462794 | First In Human Study of CX-801 in Advanced Solid Tumors | recruiting | Phase 1 | 121 | CytomX TherapeuticsINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06598735 | A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 290 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06682780 | A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 320 | LaNova Medicines LimitedINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03207672 | Study of E7389 Liposomal Formulation in Participants With Solid Tumor | active not recruiting | Phase 1 | 140 | Eisai Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04794972 | A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors | recruiting | Phase 1 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05038150 | Study of SGN1 in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 70 | Guangzhou Sinogen Pharmaceutical Co., LtdOTHER | 2 | Aug 27, 2026 | clinicaltrials |
| NCT05103345 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 70 | Guangzhou Sinogen Pharmaceutical Co., LtdOTHER | 2 | Aug 27, 2026 | clinicaltrials |
| NCT05470348 | A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05700084 | Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 84 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2026source: clinicaltrials